On November 5, 2026, Orchestra BioMed Holdings, Inc. entered into an underwriting agreement for a public offering of common stock. The offering raised approximately $86.3 million, which will be used to fund specific biotechnology programs and general corporate purposes. The offering closed on November 9, 2026, after the underwriters exercised their option for additional shares.
Who to call at Orchestra BioMed Holdings, and when
A new round usually means Orchestra BioMed Holdings is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Orchestra BioMed Holdings raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Orchestra BioMed Holdings, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Orchestra BioMed Holdings. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Orchestra BioMed Holdings
Location
London, England, United Kingdom
About
Orchestra BioMed Holdings, Inc. is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Its lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, and it is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Orchestra BioMed Holdings raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LondonManufacturingBiotechnologyHealth CareMedicalMedical Device